1
|
Caliez J, Riou M, Manaud G, Nakhleh MK, Quatredeniers M, Rucker-Martin C, Dorfmüller P, Lecerf F, Vinhas MC, Khatib S, Haick H, Cohen-Kaminsky S, Humbert M, Montani D, Perros F. Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary veno-occlusive disease. Pulm Circ 2020; 10:2045894020907884. [PMID: 33149891 PMCID: PMC7580174 DOI: 10.1177/2045894020907884] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2019] [Accepted: 01/24/2020] [Indexed: 11/16/2022] Open
Abstract
Trichloroethylene exposure is a major risk factor for pulmonary veno-occlusive disease. We demonstrated that trichloroethylene alters the endothelial barrier integrity, at least in part, through vascular endothelial (VE)-Cadherin internalisation, and suggested that this mechanism may play a role in the development of pulmonary veno-occlusive disease.
Collapse
Affiliation(s)
- Julien Caliez
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Marianne Riou
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Le Kremlin-Bicêtre, France.,Pneumologie, Hopitaux universitaires de Strasbourg, Strasbourg, France
| | - Grégoire Manaud
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Morad K Nakhleh
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Marceau Quatredeniers
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Catherine Rucker-Martin
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, France
| | - Peter Dorfmüller
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, France
| | - Florence Lecerf
- INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, France
| | - Maria C Vinhas
- INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, France
| | - Salam Khatib
- Département of Chemical Engineering and Russel Berrie Nanotechnology Institute, Haifa, Israel
| | - Hossam Haick
- Département of Chemical Engineering and Russel Berrie Nanotechnology Institute, Haifa, Israel
| | - Sylvia Cohen-Kaminsky
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Marc Humbert
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - David Montani
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Frédéric Perros
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| |
Collapse
|
2
|
Lambert M, Capuano V, Boet A, Tesson L, Bertero T, Nakhleh MK, Remy S, Anegon I, Pechoux C, Hautefort A, Rucker-Martin C, Manoury B, Domergue V, Mercier O, Girerd B, Montani D, Perros F, Humbert M, Antigny F. Characterization of Kcnk3-Mutated Rat, a Novel Model of Pulmonary Hypertension. Circ Res 2019; 125:678-695. [PMID: 31347976 DOI: 10.1161/circresaha.119.314793] [Citation(s) in RCA: 62] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
RATIONALE Pulmonary arterial hypertension is a severe lethal cardiopulmonary disease. Loss of function mutations in KCNK3 (potassium channel subfamily K member 3) gene, which encodes an outward rectifier K+ channel, have been identified in pulmonary arterial hypertension patients. OBJECTIVE We have demonstrated that KCNK3 dysfunction is common to heritable and nonheritable pulmonary arterial hypertension and to experimental pulmonary hypertension (PH). Finally, KCNK3 is not functional in mouse pulmonary vasculature. METHODS AND RESULTS Using CRISPR/Cas9 technology, we generated a 94 bp out of frame deletion in exon 1 of Kcnk3 gene and characterized these rats at the electrophysiological, echocardiographic, hemodynamic, morphological, cellular, and molecular levels to decipher the cellular mechanisms associated with loss of KCNK3. Using patch-clamp technique, we validated our transgenic strategy by demonstrating the absence of KCNK3 current in freshly isolated pulmonary arterial smooth muscle cells from Kcnk3-mutated rats. At 4 months of age, echocardiographic parameters revealed shortening of the pulmonary artery acceleration time associated with elevation of the right ventricular systolic pressure. Kcnk3-mutated rats developed more severe PH than wild-type rats after monocrotaline exposure or chronic hypoxia exposure. Kcnk3-mutation induced a lung distal neomuscularization and perivascular extracellular matrix activation. Lungs of Kcnk3-mutated rats were characterized by overactivation of ERK1/2 (extracellular signal-regulated kinase1-/2), AKT (protein kinase B), SRC, and overexpression of HIF1-α (hypoxia-inducible factor-1 α), survivin, and VWF (Von Willebrand factor). Linked with plasma membrane depolarization, reduced endothelial-NOS expression and desensitization of endothelial-derived hyperpolarizing factor, Kcnk3-mutated rats presented predisposition to vasoconstriction of pulmonary arteries and a severe loss of sildenafil-induced pulmonary arteries relaxation. Moreover, we showed strong alteration of right ventricular cardiomyocyte excitability. Finally, Kcnk3-mutated rats developed age-dependent PH associated with low serum-albumin concentration. CONCLUSIONS We established the first Kcnk3-mutated rat model of PH. Our results confirm that KCNK3 loss of function is a key event in pulmonary arterial hypertension pathogenesis. This model presents new opportunities for understanding the initiating mechanisms of PH and testing biologically relevant therapeutic molecules in the context of PH.
Collapse
Affiliation(s)
- Mélanie Lambert
- From the University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M. H., F.A.).,Assistance Publique Hôpitaux de Paris, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.).,Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.)
| | - Véronique Capuano
- From the University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M. H., F.A.).,Assistance Publique Hôpitaux de Paris, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.).,Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.)
| | - Angèle Boet
- From the University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M. H., F.A.).,Assistance Publique Hôpitaux de Paris, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.).,Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.)
| | - Laurent Tesson
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, France (L.T., S.R., I.A.).,PTransgenic Rat ImmunoPhenomic (TRIP) facility Nantes, Nantes, France (L.T., S.R., I.A.)
| | - Thomas Bertero
- Université Côte d'Azur, CNRS, IPMC, Valbonne, France (T.B.)
| | - Morad K Nakhleh
- From the University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M. H., F.A.).,Assistance Publique Hôpitaux de Paris, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.).,Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.)
| | - Séverine Remy
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, France (L.T., S.R., I.A.).,PTransgenic Rat ImmunoPhenomic (TRIP) facility Nantes, Nantes, France (L.T., S.R., I.A.)
| | - Ignacio Anegon
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, France (L.T., S.R., I.A.).,PTransgenic Rat ImmunoPhenomic (TRIP) facility Nantes, Nantes, France (L.T., S.R., I.A.)
| | - Christine Pechoux
- GABI, INRA, AgroParisTech, Université Paris-Saclay, 78350 Jouy-en-Josas, France (C.P.)
| | - Aurélie Hautefort
- From the University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M. H., F.A.).,Assistance Publique Hôpitaux de Paris, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.).,Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.)
| | - Catherine Rucker-Martin
- From the University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M. H., F.A.).,Assistance Publique Hôpitaux de Paris, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.).,Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.)
| | - Boris Manoury
- Signalisation et Physiopathologie Cardiovasculaire - UMR_S 1180, Univ. Paris-Sud, INSERM, Université Paris-Saclay, Châtenay-Malabry, France (B.M.)
| | - Valérie Domergue
- Animal Facility, Institut Paris Saclay d'Innovation Thérapeutique (UMS IPSIT), Université Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France (V.D.)
| | - Olaf Mercier
- From the University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M. H., F.A.).,Assistance Publique Hôpitaux de Paris, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.).,Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.)
| | - Barbara Girerd
- From the University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M. H., F.A.).,Assistance Publique Hôpitaux de Paris, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.).,Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.)
| | - David Montani
- From the University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M. H., F.A.).,Assistance Publique Hôpitaux de Paris, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.).,Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.)
| | - Frédéric Perros
- From the University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M. H., F.A.).,Assistance Publique Hôpitaux de Paris, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.).,Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.).,Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Canada (F.P.)
| | - Marc Humbert
- From the University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M. H., F.A.).,Assistance Publique Hôpitaux de Paris, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.).,Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.)
| | - Fabrice Antigny
- From the University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M. H., F.A.).,Assistance Publique Hôpitaux de Paris, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.).,Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (M.L., V.C., A.B., M.K.N., A.H., C.R.-M., O.M., B.G., D.M., F.P., M.H., F.A.)
| |
Collapse
|
3
|
Einoch Amor R, Nakhleh MK, Barash O, Haick H. Breath analysis of cancer in the present and the future. Eur Respir Rev 2019; 28:28/152/190002. [DOI: 10.1183/16000617.0002-2019] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2019] [Accepted: 05/19/2019] [Indexed: 12/11/2022] Open
Abstract
Most of the currently used diagnostics for cancerous diseases have yet to meet the standards of screening, as they are insufficiently accurate and/or invasive and risky. In this review, we describe the rationale, the progress made to date, and the potential of analysing the exhaled volatile organic compounds as a pathway for enabling early diagnosis of cancer and, therefore, for achieving better clinical prognosis and survival rates. The review highlights the major advancements made in this field, from fundamentals, up to translational phases and clinical trials, with a special emphasis on sensing platforms based on nanomaterials. The prospects for breath analysis in early cancerous disease are presented and discussed.
Collapse
|
4
|
Gaude E, Nakhleh MK, Patassini S, Boschmans J, Allsworth M, Boyle B, van der Schee MP. Targeted breath analysis: exogenous volatile organic compounds (EVOC) as metabolic pathway-specific probes. J Breath Res 2019; 13:032001. [DOI: 10.1088/1752-7163/ab1789] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
5
|
Quatredeniers M, Nakhleh MK, Dumas SJ, Courboulin A, Vinhas MC, Antigny F, Phan C, Guignabert C, Bendifallah I, Vocelle M, Fadel E, Dorfmüller P, Humbert M, Cohen-Kaminsky S. Functional interaction between PDGFβ and GluN2B-containing NMDA receptors in smooth muscle cell proliferation and migration in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2018; 316:L445-L455. [PMID: 30543306 DOI: 10.1152/ajplung.00537.2017] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
In this study, we explored the complex interactions between platelet-derived growth factor (PDGF) and N-methyl-d-aspartate receptor (NMDAR) and their effect on the excessive proliferation and migration of smooth muscle cells leading to obstructed arteries in pulmonary arterial hypertension (PAH). We report lower expression of glutamate receptor NMDA-type subunit 2B (GluN2B), a subunit composing NMDARs expected to affect cell survival/proliferation of pulmonary artery smooth muscle cells (PASMCs), in PAH patient lungs. PASMC exposure to PDGF-BB stimulated immediate increased levels of phosphorylated Src family kinases (SFKs) together with increased phosphorylated GluN2B (its active form) and cell surface relocalization, suggesting a cross talk between PDGFR-recruited SFKs and NMDAR. Selective inhibition of PDGFR-β or SFKs with imatinib or A-419259, respectively, on one hand, or with specific small-interfering RNAs (siRNAs) on the other hand, aborted PDGF-induced phosphorylation of GluN2B, thus validating the pathway. Selective inhibition of GluN2B using Rö25-6981 and silencing with specific siRNA, in the presence of PDGF-BB, significantly increased both migration and proliferation of PASMCs, thus strengthening the functional importance of the pathway. Together, these results indicate that GluN2B-type NMDAR activation may confer to PASMCs antiproliferative and antimigratory properties. The decreased levels of GluN2B observed in PAH pulmonary arteries could mediate the excessive proliferation of PASMCs, thus contributing to medial hyperplasia and PAH development.
Collapse
Affiliation(s)
- Marceau Quatredeniers
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Morad K Nakhleh
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Sébastien J Dumas
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Audrey Courboulin
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Maria C Vinhas
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Fabrice Antigny
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Carole Phan
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Christophe Guignabert
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Imane Bendifallah
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Matthieu Vocelle
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Elie Fadel
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Peter Dorfmüller
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Marc Humbert
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.,AP-HP Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Sylvia Cohen-Kaminsky
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| |
Collapse
|
6
|
Finberg JPM, Schwartz M, Jeries R, Badarny S, Nakhleh MK, Abu Daoud E, Ayubkhanov Y, Aboud-Hawa M, Broza YY, Haick H. Sensor Array for Detection of Early Stage Parkinson's Disease before Medication. ACS Chem Neurosci 2018; 9:2548-2553. [PMID: 29989795 DOI: 10.1021/acschemneuro.8b00245] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Early diagnosis of Parkinson's disease (PD) is important because it affects the choice of therapy and is subject to a relatively high degree of error. In addition, early detection of PD can potentially enable the start of neuroprotective therapy before extensive loss of dopaminergic neurons of the substantia nigra occurs. However, until now, studies for early detection of PD using volatile biomarkers sampled only treated and medicated patients. Therefore, there is a great need to evaluate untreated patients for establishing a real world screening and diagnostic technology. Here we describe for the first time a clinical trial to distinguish between de novo PD and control subjects using an electronic system for detection of volatile molecules in exhaled breath (sensor array). We further determine for the first time the association to other common tests for PD diagnostics as smell, ultrasound, and nonmotor symptoms. The test group consisted of 29 PD patients after initial diagnosis by an experienced neurologist, compared with 19 control subjects of similar age. The sensitivity, specificity, and accuracy values of the sensor array to detect PD from controls were 79%, 84%, and 81% respectively, in comparison with midbrain ultrasonography (93%, 90%, 92%) and smell detection (62%, 89%, 73%). The results confirm previous data showing the potential of sensor arrays to detect PD.
Collapse
Affiliation(s)
- John P. M. Finberg
- Neuroscience Department, Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Miguel Schwartz
- Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Raneen Jeries
- Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Samih Badarny
- Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Morad K. Nakhleh
- Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Enas Abu Daoud
- Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Yelena Ayubkhanov
- Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Manal Aboud-Hawa
- Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Yoav Y Broza
- Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Hossam Haick
- Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| |
Collapse
|
7
|
Broza YY, Vishinkin R, Barash O, Nakhleh MK, Haick H. Synergy between nanomaterials and volatile organic compounds for non-invasive medical evaluation. Chem Soc Rev 2018; 47:4781-4859. [PMID: 29888356 DOI: 10.1039/c8cs00317c] [Citation(s) in RCA: 109] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
This article is an overview of the present and ongoing developments in the field of nanomaterial-based sensors for enabling fast, relatively inexpensive and minimally (or non-) invasive diagnostics of health conditions with follow-up by detecting volatile organic compounds (VOCs) excreted from one or combination of human body fluids and tissues (e.g., blood, urine, breath, skin). Part of the review provides a didactic examination of the concepts and approaches related to emerging sensing materials and transduction techniques linked with the VOC-based non-invasive medical evaluations. We also present and discuss diverse characteristics of these innovative sensors, such as their mode of operation, sensitivity, selectivity and response time, as well as the major approaches proposed for enhancing their ability as hybrid sensors to afford multidimensional sensing and information-based sensing. The other parts of the review give an updated compilation of the past and currently available VOC-based sensors for disease diagnostics. This compilation summarizes all VOCs identified in relation to sickness and sampling origin that links these data with advanced nanomaterial-based sensing technologies. Both strength and pitfalls are discussed and criticized, particularly from the perspective of the information and communication era. Further ideas regarding improvement of sensors, sensor arrays, sensing devices and the proposed workflow are also included.
Collapse
Affiliation(s)
- Yoav Y Broza
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion - Israel Institute of Technology, Haifa 3200003, Israel.
| | | | | | | | | |
Collapse
|
8
|
Finberg JPM, Aluf Y, Loboda Y, Nakhleh MK, Jeries R, Abud-Hawa M, Zubedat S, Avital A, Khatib S, Vaya J, Haick H. Altered Volatile Organic Compound Profile in Transgenic Rats Bearing A53T Mutation of Human α-Synuclein: Comparison with Dopaminergic and Serotonergic Denervation. ACS Chem Neurosci 2018; 9:291-297. [PMID: 29017011 DOI: 10.1021/acschemneuro.7b00318] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Early diagnosis of Parkinson's disease (PD) is of great importance due its progressive phenotype. Neuroprotective drugs could potentially slow down disease progression if used at early stages. Previously, we have reported an altered content of volatile organic compounds (VOCs) in the breath of rats following a 50% reduction in striatal dopamine (DA) content induced by 6-hydroxydopamine. We now report on the difference in the breath-print and content of VOCs between rats with mild and severe lesions of DA neurons, serotonergic neuronal lesions, and transgenic (Tg) rats carrying the PD-producing A53T mutation of the SNCA (α-synuclein) gene. The Tg rats had an increased content of 3-octen-1-ol and 4-chloro-3-methyl phenol in blood, while in brain tissue, hexanal, hexanol, and 2,3-octanedione were present in controls but absent in Tg rats. Levels of 1-heptyl-2-methyl cyclopropane were increased in brain tissue of Tg rats. The data confirm the potential of breath analysis for detection of human idiosyncratic as well as autosomal dominant PD.
Collapse
Affiliation(s)
- John P. M. Finberg
- Neuroscience Department,
Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Yuval Aluf
- Neuroscience Department,
Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Yelena Loboda
- Neuroscience Department,
Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Morad K. Nakhleh
- Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Raneen Jeries
- Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Manal Abud-Hawa
- Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Salman Zubedat
- Neuroscience Department,
Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Avi Avital
- Neuroscience Department,
Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Soliman Khatib
- Laboratory of Natural Medicinal Compounds, Migal-Galilee Research
Institute, Kiryat Shmona and Tel Hai College, Qiryat Shemona, 1220800, Israel
| | - Jacob Vaya
- Laboratory of Natural Medicinal Compounds, Migal-Galilee Research
Institute, Kiryat Shmona and Tel Hai College, Qiryat Shemona, 1220800, Israel
| | - Hossam Haick
- Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| |
Collapse
|
9
|
Dumas SJ, Bru-Mercier G, Courboulin A, Quatredeniers M, Rücker-Martin C, Antigny F, Nakhleh MK, Ranchoux B, Gouadon E, Vinhas MC, Vocelle M, Raymond N, Dorfmüller P, Fadel E, Perros F, Humbert M, Cohen-Kaminsky S. NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension. Circulation 2018; 137:2371-2389. [PMID: 29444988 DOI: 10.1161/circulationaha.117.029930] [Citation(s) in RCA: 71] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Accepted: 12/22/2017] [Indexed: 12/15/2022]
Abstract
BACKGROUND Excessive proliferation and apoptosis resistance in pulmonary vascular cells underlie vascular remodeling in pulmonary arterial hypertension (PAH). Specific treatments for PAH exist, mostly targeting endothelial dysfunction, but high pulmonary arterial pressure still causes heart failure and death. Pulmonary vascular remodeling may be driven by metabolic reprogramming of vascular cells to increase glutaminolysis and glutamate production. The N-methyl-d-aspartate receptor (NMDAR), a major neuronal glutamate receptor, is also expressed on vascular cells, but its role in PAH is unknown. METHODS We assessed the status of the glutamate-NMDAR axis in the pulmonary arteries of patients with PAH and controls through mass spectrometry imaging, Western blotting, and immunohistochemistry. We measured the glutamate release from cultured pulmonary vascular cells using enzymatic assays and analyzed NMDAR regulation/phosphorylation through Western blot experiments. The effect of NMDAR blockade on human pulmonary arterial smooth muscle cell proliferation was determined using a BrdU incorporation assay. We assessed the role of NMDARs in vascular remodeling associated to pulmonary hypertension, in both smooth muscle-specific NMDAR knockout mice exposed to chronic hypoxia and the monocrotaline rat model of pulmonary hypertension using NMDAR blockers. RESULTS We report glutamate accumulation, upregulation of the NMDAR, and NMDAR engagement reflected by increases in GluN1-subunit phosphorylation in the pulmonary arteries of human patients with PAH. Kv channel inhibition and type A-selective endothelin receptor activation amplified calcium-dependent glutamate release from human pulmonary arterial smooth muscle cell, and type A-selective endothelin receptor and platelet-derived growth factor receptor activation led to NMDAR engagement, highlighting crosstalk between the glutamate-NMDAR axis and major PAH-associated pathways. The platelet-derived growth factor-BB-induced proliferation of human pulmonary arterial smooth muscle cells involved NMDAR activation and phosphorylated GluN1 subunit localization to cell-cell contacts, consistent with glutamatergic communication between proliferating human pulmonary arterial smooth muscle cells via NMDARs. Smooth-muscle NMDAR deficiency in mice attenuated the vascular remodeling triggered by chronic hypoxia, highlighting the role of vascular NMDARs in pulmonary hypertension. Pharmacological NMDAR blockade in the monocrotaline rat model of pulmonary hypertension had beneficial effects on cardiac and vascular remodeling, decreasing endothelial dysfunction, cell proliferation, and apoptosis resistance while disrupting the glutamate-NMDAR pathway in pulmonary arteries. CONCLUSIONS These results reveal a dysregulation of the glutamate-NMDAR axis in the pulmonary arteries of patients with PAH and identify vascular NMDARs as targets for antiremodeling treatments in PAH.
Collapse
MESH Headings
- Animals
- Apoptosis/drug effects
- Calcium/pharmacology
- Cell Proliferation/drug effects
- Disease Models, Animal
- Dizocilpine Maleate/pharmacology
- Endothelin-1/pharmacology
- Glutamic Acid/metabolism
- Humans
- Hypertension, Pulmonary/metabolism
- Hypertension, Pulmonary/pathology
- Lung/metabolism
- Lung/pathology
- Mice
- Mice, Knockout
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- Potassium Channels, Voltage-Gated/metabolism
- Rats
- Receptors, Endothelin/chemistry
- Receptors, Endothelin/metabolism
- Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors
- Receptors, N-Methyl-D-Aspartate/genetics
- Receptors, N-Methyl-D-Aspartate/metabolism
- Signal Transduction/drug effects
- Vascular Remodeling/drug effects
Collapse
Affiliation(s)
- Sébastien J Dumas
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Gilles Bru-Mercier
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Audrey Courboulin
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Marceau Quatredeniers
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Catherine Rücker-Martin
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Fabrice Antigny
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Morad K Nakhleh
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Benoit Ranchoux
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Elodie Gouadon
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Maria-Candida Vinhas
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Matthieu Vocelle
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Nicolas Raymond
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Peter Dorfmüller
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Elie Fadel
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Frédéric Perros
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| | - Marc Humbert
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
- AP-HP Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France (M.H.)
| | - Sylvia Cohen-Kaminsky
- INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.).
- University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (S.J.D., G.B.-M., A.C., M.Q., C.R.-M, F.A., M.K.N., B.R., E.G., M.-C.V., M.V., N.R., P.D., E.F., F.P., M.H., S.C.-K.)
| |
Collapse
|
10
|
Affiliation(s)
- MK Nakhleh
- Univ Paris-Sud; Faculté de Médecine; Université Paris-Saclay; Le Kremlin Bicêtre France
- AP-HP; DHU TORINO; Service de Pneumologie; Hôpital Bicêtre; Le Kremlin Bicêtre France
- Inserm UMR_S 999; LabExLERMIT; Hôpital Marie Lannelongue; Le Plessis Robinson France
| | - M Quatredeniers
- Univ Paris-Sud; Faculté de Médecine; Université Paris-Saclay; Le Kremlin Bicêtre France
- AP-HP; DHU TORINO; Service de Pneumologie; Hôpital Bicêtre; Le Kremlin Bicêtre France
- Inserm UMR_S 999; LabExLERMIT; Hôpital Marie Lannelongue; Le Plessis Robinson France
| | - H Haick
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute; Technion-Israel Institute of Technology; Haifa Israel
| |
Collapse
|
11
|
Nakhleh MK, Haick H, Humbert M, Cohen-Kaminsky S. Volatolomics of breath as an emerging frontier in pulmonary arterial hypertension. Eur Respir J 2017; 49:49/2/1601897. [DOI: 10.1183/13993003.01897-2016] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2016] [Accepted: 11/15/2016] [Indexed: 01/26/2023]
Abstract
There is accumulating evidence in support of the significant improvement in survival rates and clinical outcomes when pulmonary arterial hypertension (PAH) is diagnosed at early stages. Nevertheless, it remains a major clinical challenge and the outcomes are dependent on invasive right heart catheterisation.Resulting from pathophysiological processes and detectable in exhaled breath, volatile organic compounds (VOCs) have been proposed as noninvasive biomarkers for PAH. Studies have confirmed significant alterations of the exhaled VOCs among PAH patients when compared to controls and/or patients with other respiratory diseases. This suggests exhaled breath analysis as a potential noninvasive medical application in the field of PAH.In this article, we review and discuss the progress made so far in the field of exhaled volatolomics (the omics of VOCs) as a potential noninvasive diagnostics of PAH. In addition, we propose a model including possible biochemical pathways on the level of the remodelled artery, in which specific VOCs could be detectable in exhaled breath during the early phases of PAH. We debate the different analytical approaches used and recommend a diagram including a “bottom–top” strategy, from basic to translational studies, required for promoting the field.
Collapse
|
12
|
Karban A, Nakhleh MK, Cancilla JC, Vishinkin R, Rainis T, Koifman E, Jeries R, Ivgi H, Torrecilla JS, Haick H. Programmed Nanoparticles for Tailoring the Detection of Inflammatory Bowel Diseases and Irritable Bowel Syndrome Disease via Breathprint. Adv Healthc Mater 2016; 5:2339-44. [PMID: 27390291 DOI: 10.1002/adhm.201600588] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2016] [Revised: 06/14/2016] [Indexed: 12/17/2022]
Abstract
Chemical sensors based on programmable molecularly modified gold nanoparticles are tailored for the detection and discrimination between the breathprint of irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD). The sensors are examined in both lab- and real-world clinical conditions. The results reveal a discriminative power accuracy of 81% between IBD and IBS and 75% between Crohn's and Colitis states.
Collapse
Affiliation(s)
- Amir Karban
- Internal Medicine C and Gastroenterology Departments at Rambam Medical Center, Rappaport School of Medicine at Technion-Israel Institute of Technology, Haifa, 3109610, Israel
| | - Morad K Nakhleh
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, 3200003, Israel
| | - John C Cancilla
- Department of Chemical Engineering, Complutense University of Madrid, Madrid, 28040, Spain
| | - Rotem Vishinkin
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, 3200003, Israel
| | - Tova Rainis
- Department of Gastroenterology at Bnai Zion Hospital, Rappaport School of Medicine at Technion-Israel Institute of Technology, Haifa, 31048, Israel
| | - Eduard Koifman
- Internal Medicine C and Gastroenterology Departments at Rambam Medical Center, Rappaport School of Medicine at Technion-Israel Institute of Technology, Haifa, 3109610, Israel
| | - Raneen Jeries
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, 3200003, Israel
| | - Hodaya Ivgi
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, 3200003, Israel
| | - Jose S Torrecilla
- Department of Chemical Engineering, Complutense University of Madrid, Madrid, 28040, Spain
| | - Hossam Haick
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, 3200003, Israel.
| |
Collapse
|
13
|
Abstract
The recognition of volatile organic compounds in breath samples is a promising approach for noninvasive safe diagnosis of disease. Spectrometry and spectroscopy methods used for breath analysis suffer from suboptimal accuracy, are expensive and are unsuitable for diagnostics. This article presents a concise review on arrays of monolayer-capped gold nanoparticle (GNP) sensors in conjugation with pattern recognition methods for cost-effective, fast and high-throughput point-of-care diagnostic results from exhaled breath samples. The article starts with a general introduction to the rationale and advantages of breath analysis as well as with a presentation of the utility of monolayer-capped GNP sensors in this field. The article continues with a presentation of the main fabrication and operation principles of these GNP sensors and concludes with selected examples regarding their utility in different fields of medicine, particularly in neurology, infectiology, respiratory medicine and oncology.
Collapse
Affiliation(s)
- Morad K Nakhleh
- Department of Chemical Engineering & Russell Berrie Nanotechnology Institute Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | | | | |
Collapse
|
14
|
Nakhleh MK, Jeries R, Gharra A, Binder A, Broza YY, Pascoe M, Dheda K, Haick H. Detecting active pulmonary tuberculosis with a breath test using nanomaterial-based sensors. Eur Respir J 2014; 43:1522-5. [PMID: 24789953 DOI: 10.1183/09031936.00019114] [Citation(s) in RCA: 81] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
15
|
Nakhleh MK, Badarny S, Winer R, Jeries R, Finberg J, Haick H. Distinguishing idiopathic Parkinson's disease from other parkinsonian syndromes by breath test. Parkinsonism Relat Disord 2014; 21:150-3. [PMID: 25511331 DOI: 10.1016/j.parkreldis.2014.11.023] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2014] [Revised: 11/12/2014] [Accepted: 11/27/2014] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Diagnosis of different parkinsonian syndromes is linked with high misdiagnosis rates and various confounding factors. This is particularly problematic in its early stages. With this in mind, the current pilot study aimed to distinguish between Idiopathic Parkinson's Disease (iPD), other Parkinsonian syndromes (non-iPD) and healthy subjects, by a breath test that analyzes the exhaled volatile organic compounds using a highly sensitive nanoarray. METHODS Breath samples of 44 iPD, 16 non-iPD patients and 37 healthy controls were collected. The samples were passed over a nanoarray and the resulting electrical signals were analyzed with discriminant factor analysis as well as by a K-fold cross-validation method, to test the accuracy of the model. RESULTS Comparison of non-iPD with iPD states yielded 88% sensitivity, 88% accuracy, and 88% Receiver Operating Characteristic area under the curve in the training set samples with known identity. The validation set of this comparison scored 81% sensitivity and accuracy and 92% negative predictive value. Comparison between atypical parkinsonism states and healthy subjects scored 94% sensitivity and 85% accuracy in the training set samples with known identity. The validation set of this comparison scored 81% sensitivity and 78% accuracy. The obtained results were not affected by l-Dopa or MAO-B inhibitor treatment. CONCLUSIONS Exhaled breath analysis with nanoarray is a promising approach for a non-invasive, inexpensive, and portable technique for differentiation between different Parkinsonian states. A larger cohort is required in order to establish the clinical usefulness of the method.
Collapse
Affiliation(s)
- M K Nakhleh
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - S Badarny
- Movement Disorders Clinic, Department of Neurology, Carmel Medical Center, and Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel.
| | - R Winer
- Movement Disorders Clinic, Department of Neurology, Carmel Medical Center, and Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - R Jeries
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - J Finberg
- Department of Molecular Pharmacology, Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 31096, Israel
| | - H Haick
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion - Israel Institute of Technology, Haifa 3200003, Israel.
| |
Collapse
|